Glutamatergic Modulators in Depression
Harvard Review of Psychiatry February 21, 2018 Ioline D. Henter, Rafael Teixeira de Sousa, Carlos A. Zarate 94 citations
Glutamatergic system dysfunction is implicated in bipolar depression and major depressive disorder. Subanesthetic doses of ketamine produce rapid reductions in depressive symptoms, prompting the development of other glutamatergic modulators. This review highlights evidence for antidepressant effects of broad modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine, AVP-786, nitrous oxide, AZD6765), NR2B-specific NMDA receptor antagonists (traxoprodil, MK-0657), glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and metabotropic glutamate receptor modulators (AZD2066, basimglurant, JNJ40411813, RG1578).